Aldeyra to Appeal FDA Rejection of Reproxalap for Dry Eye Disease

Aldeyra Therapeutics NASDAQ: ALDX said it plans to submit a formal dispute resolution request, or FDRR, to the FDA's Office of New Drugs seeking review of the agency's latest complete response letter for reproxalap, its investigational treatment for the signs and symptoms of dry eye disease.

MarketBeat • Sep 29, 2026

Aldeyra Fights Back Against FDA Rejection, Dispute Plan Triggers Rally

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) shares are trading higher on Tuesday as investors react to the company's intent to submit a formal dispute resolution request tied to its reproxalap program.

Benzinga • Sep 29, 2026

Aldeyra Therapeutics, Inc. (ALDX) Discusses FDRR and FDA Review Process for Reproxalap in Dry Eye Disease Transcript

Aldeyra Therapeutics, Inc. (ALDX) Discusses FDRR and FDA Review Process for Reproxalap in Dry Eye Disease Transcript

Seeking Alpha • Sep 29, 2026

Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye Disease

CONCORD, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced intent to submit to the U.S. Food and Drug Administration (FDA) a Formal Dispute Resolution Request (FDRR) for reproxalap, an investigational drug candidate, for the treatment of dry eye disease. The FDRR, which is expected to be reviewed by the FDA's Office of New Drug.

Business Wire • Sep 29, 2026

Aldeyra Therapeutics to Host Regulatory Update Webcast

CONCORD, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that the company will host a regulatory update webcast on Tuesday, September 29, 2026, at 8:00 a.m. ET. The update will focus on reproxalap, an investigational drug for the treatment of dry eye disease. A live audio webcast and slide presentation will be accessible from.

Business Wire • Sep 28, 2026

Levicept Appoints Darlene Deptula-Hicks as CFO

Highly Experienced US-Based Public Markets Leader Strengthens Team as Company Drives Late Stage Development of LEVI-04 for Osteoarthritis Highly Experienced US-Based Public Markets Leader Strengthens Team as Company Drives Late Stage Development of LEVI-04 for Osteoarthritis

GlobeNewsWire • Jul 7, 2026

Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced the appointment of Darlene Deptula-Hicks to Aldeyra's board of directors (the Board). “Ms. Deptula-Hicks brings decades of experience working with both publicly traded and venture-backed biotechnology companies,” stated Richard H. Douglas, Ph.D., Chairman of the Board.

Business Wire • Jun 10, 2026

Aldeyra Therapeutics Eyes FDA Feedback as Dry Eye Drug Faces Make-or-Break Moment

Aldeyra Therapeutics NASDAQ: ALDX Chief Executive Todd Brady said the company expects near-term feedback from the U.S. Food and Drug Administration on its dry eye disease candidate reproxalap, following a third complete response letter tied to efficacy questions.

MarketBeat • Jun 5, 2026

Aldeyra Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in New York, New York. Dr. Brady's conversation with Amin Makarem, Vice President, Biotechnology Equity Resea.

Business Wire • Jun 2, 2026

ALDX FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026

NEW YORK--(BUSINESS WIRE)---- $ALDX #ALDX--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ: ALDX) and reminds investors of the May 29, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The.

Business Wire • May 29, 2026